Uses of Cadirabe

Cadirabe drug is made in the form of hard capsules with the main ingredient being Rabeprazole. The drug is used in the treatment of certain diseases of the gastrointestinal tract.

Each Cadirabe tablet contains 10mg of Rabeprazole sodium and other excipients. Rabeprazole is an inhibitor of H+, K+, -ATPase.
Rabeprazole inhibits gastric acid secretion:
In vitro, Rabeprazole sodium inhibits gastric acid secretion stimulated by dibutyl cyclic AMP in the gastric glands of rabbits; Rabeprazole sodium strongly inhibits pentagastrin- or histamine-stimulated gastric acid secretion in dogs with chronic gastric fistula as well as normal or histamine-stimulated gastric acid secretion in rats. Compared with other proton pump inhibitors, the reversal of antisecretory activity of rabeprazole sodium is more rapid and the increase in blood gastrin levels is lower with that of rabeprazole sodium.
In addition, Rabeprazole sodium has a strong anti-ulcer effect in rats for a variety of ulcers and improves experimental gastric mucosal lesions (stress due to immersion in water, stress due to cold infection, pyloric ligation, etc.). using ethanol-HCl or cysteine).
Cadirabe is used in:
Treatment of duodenal ulcers; Treatment of gastroesophageal reflux disease; Treatment of Zollinger-Ellison syndrome. Do not use Cadirabe for people who are sensitive to any of the ingredients in the drug or benzimidazole derivatives.

2.1. How to take Cadirabe drug is used by direct oral administration. Note: Cadirabe enteric-soluble tablets should be swallowed whole; Do not chew, crush or break the tablet. In addition, because the drug is soluble in the intestine, it can be taken with or without food.
2.2. Dosage For adults (children should not use the drug):
Treatment of gastroesophageal reflux disease (GERD): Use a dose of 20mg / time / day x 4 - 8 weeks, can be used for an additional 8 weeks necessary; Treatment of duodenal ulcer: Use dose 20mg/time/day x 4 weeks; Treatment of Zollinger - Ellison syndrome: Initial dose is 60mg/time/day and adjust dose according to patient's response; Treatment of gastroesophageal reflux disease causing ulceration or erosion: The recommended oral dose is 20mg/time/day for 4-8 weeks. For patients who do not heal after 8 weeks of treatment, an additional 8 weeks can be used; Maintenance after healing of erosive or ulcerative gastroesophageal reflux disease: The recommended oral dose is 20mg/time/day; Treatment of symptomatic gastroesophageal reflux disease: The recommended oral dose is 20mg/time/day x 4 weeks. If complete resolution of symptoms is not achieved after 4 weeks, an additional course of treatment may be used; Healing of duodenal ulcer: The recommended oral dose is 20mg once a day, taken after breakfast with a course of treatment lasting about 4 weeks. Most patients heal a duodenal ulcer within 4 weeks, some patients may need an additional course of treatment to heal the ulcer; Combination of antibiotics in the treatment of people infected with Helicobacter pylori to reduce the risk of duodenal ulcer recurrence: Using Rabeprazole in combination with antibiotics to destroy Helicobacter pylori; Patients with renal and hepatic impairment: No dose adjustment is required for Cadirabe. Note: Patients need to use Cadirabe at the right dose, avoid missing doses, and do not arbitrarily make up for a missed dose of Cadirabe without a doctor's instructions to avoid dangerous side effects.

During the use of Cadirabe, patients may experience some side effects such as: Fever, weakness, chills, allergic reactions, chest pain below the sternum, fatigue, photosensitivity, stiff neck , dry mouth , digestive disorders , rectal bleeding , black stools , belching , gallstones , anorexia , cholecystitis , gingivitis , increased appetite , esophagitis , pancreatitis , colitis, glossitis,...
Patients need to contact their doctor when experiencing side effects during the use of Cadirabe for prompt and timely treatment advice.

Some notes on Cadirabe's caution and drug interactions:
Caution when using Cadirabe in the following subjects: Patients with severe liver failure, pregnant or lactating women, children; Concomitant use of Cadirabe with digoxin may increase the concentration of digoxin in the blood. This mechanism is because the absorption of digoxin will be increased by increased gastric pH; Concomitant use of Cadirabe with phenytoin: There have been reports of Rabeprazole's analogues, Omeprazole, which prolong the metabolism and excretion of phenytoin; Concomitant use of Cadirabe with Antacid containing Aluminum Hydroxide Gel or Magnesium Hydroxide: A decrease in mean serum AUC concentration has been reported after concomitant use of Rabeprazole - Antacid or when Rabeprazole was used 1 hour after administration of Cadirabe. Antacids versus Rabeprazole alone. Patients should inform their doctor about the drugs they are taking before using Cadirabe to ensure that there are no drug interactions that negatively affect the body.
During the use of Cadirabe, the patient should follow the instructions given by the doctor to be able to bring the most effective treatment, to avoid unwanted incidents.